CA-MIRO
28.4.2022 13:02:12 CEST | Business Wire | Press release
Miro , the online platform accelerating innovation through visual collaboration, today announced Miro Next , an all-virtual event revealing the next big thing for hybrid teams through the latest product and partner developments from the company. Miro Next will take place on May 18, 2022, at 8am PST / 5pm CEST and is purposefully designed to empower global teams to do more together.
Everyone is looking for new ways to succeed and thrive in today’s hybrid work environments. Some of the secrets to success include meetings that are more inclusive and interactive – blurring the lines between in-person and the virtual experience. Companies will need custom integrations between critical applications to help drive productivity and simplify the user experience, and more and more organizations will adopt agile practices that increase teamwork and speed innovation. Miro Next will explore these strategies, along with a host of updates on product features and enhancements, all designed to help organizations make hybrid work.
The event will kick off with a keynote presentation by Varun Parmar, Miro’s Chief Product Officer. Joined onstage with Miro partners and featured speakers, including Jeetu Patel of Cisco and Megan Cook of Atlassian, Parmar will show how Miro’s digital whiteboard is just the beginning of the future of visual collaboration.
“Miro Next will help us rediscover how to put people at the center of hybrid work, and in doing so, drive deeper engagement and collaboration among teams,” said Parmar. “I hope that teams all around the world will join us for this one-of-a-kind experience in just a few weeks.”
Miro Next will also feature a presentation led by Thor Mitchell, Miro’s Head of Product, Developer Platform, giving attendees an up-close-and-personal look at the next generation of Miro’s Developer Platform, and why it’s the perfect product to create an integrated collaboration experience that’s quick, easy, and seamless. The Miro Developer Platform was created three years ago to give any individual or enterprise the ability to build plugins and third-party integrations, and embed live Miro boards into other apps using Miro’s open API and SDKs. The Miro Developer Platform unlocks new, custom workflows to enhance the collaborative experience. At Miro Next, Airtable, ClickUp and others will join Mitchell to show how the Miro Developer Platform has unlocked new ways to harness visual collaboration using Miro and what they’re planning in the future.
In addition to learning about the future of visual collaboration from Miro product leaders and partners, Miro Next attendees will get exclusive access to breakout sessions to share ideas, ask questions, and connect with other Miro users who are seeking new ways to co-create with their teams, both synchronously and asynchronously. Miro Next breakout sessions include:
- The Road to Accessibility: A Collaborative Journey - Join Phil Strain, Miro Lead Product Manager for Accessibility and Design, and Sheri Byrne-Haber, VMWare Senior Staff Architect for Accessibility, to explore how an inclusive mindset can be a game-changer when it comes to company and end-user engagement.
- The Hybrid Workplace: Securing and Managing Collaboration In This New Way of Working - This thought leadership panel will include industry experts from Miro, Netskope, and Onna, sharing their top insights and practices for securing and managing hybrid workforces, while creating frictionless environments that help drive collaboration and creativity.
- Connected and Aligned: Your Hybrid Team in Miro - Join Miro’s team of customer education experts to learn how to use Miro features and skills to include all voices in collaborative work and create a one-stop Miro board for teams to gather information, share resources, and align expeditiously on what’s most important.
Miro Next will help all teams jump from “what now?” to “what’s next?” and explore their collaborative potential. Be among the first to preview new Miro features and get a sneak peek into the modern visual collaboration ecosystem:
- WHEN : May 18, 2022, 8 am PT/ 5 pm CET
- WHAT : One highlight-filled keynote session (60 minutes) and three, exclusive breakout sessions (60 minutes each)
- HOW : It’s virtual! RSVP for free at miro.com/next
About Miro
Miro is an online, visual collaboration platform designed to unlock creativity and accelerate innovation among teams of all kinds. The platform’s infinite canvas enables teams to lead engaging workshops and meetings, design products, brainstorm ideas, and more. Miro, co-headquartered in San Francisco and Amsterdam, serves more than 30M users worldwide, including 99% of the Fortune 100. Miro was founded in 2011 and currently has more than 1,400 employees in 10 hubs around the world. To learn more, please visit https://miro.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005447/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom